Research graph
References from Comparative efficacy and safety of adenosine A2A receptor antagonists for Parkinson’s disease: A systematic review and network meta-analysis of randomized controlled trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Parkinson's disease
2022 · External reference
Small molecules in Parkinson's disease therapy: from dopamine pathways to new emerging targets
10.3390/ph17121688 · 2024 · External reference
Motor complications of dopaminergic medications in Parkinson's disease
10.1055/s-0037-1602423 · 2017 · External reference
Pharmacological treatment of Parkinson's disease
10.1186/1471-2318-10-s1-l30 · 2010 · External reference
In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease
10.2174/1570159x16666180308161642 · 2018 · External reference
Adenosine A(2A) receptors and A(2A) receptor heteromers as key players in striatal function
10.3389/fnana.2011.00036 · 2011 · External reference
The belated US FDA approval of the adenosine A2a receptor antagonist istradefylline for treatment of Parkinson's disease
10.1007/s11302-020-09694-2 · 2020 · External reference
Adenosine A2A antagonists in Parkinson's disease: what's next?
10.1007/s11910-012-0279-2 · 2012 · External reference
Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
10.1016/j.parkreldis.2009.06.008 · 2010 · External reference
Adenosine A2a receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)
10.1002/ana.21315 · 2008 · External reference
Adenosine A2a receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
10.1002/mds.25418 · 2013 · External reference
Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study
10.1016/j.parkreldis.2011.09.023 · 2012 · External reference
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD
10.1212/01.wnl.0000081227.84197.0b · 2003 · External reference
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
10.1002/mds.22095 · 2008 · External reference
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
10.1212/01.wnl.0000313834.22171.17 · 2008 · External reference
Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study
10.1002/mds.23107 · 2010 · External reference
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
10.1016/s1474-4422(11)70012-6 · 2011 · External reference
Adjunctive preladenant: a placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease
10.1016/j.parkreldis.2016.08.020 · 2016 · External reference
Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned
10.1001/jamaneurol.2015.2268 · 2015 · External reference
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
10.1212/wnl.0000000000004003 · 2017 · External reference
The effect of istradefylline for Parkinson's disease: a meta-analysis
10.1038/s41598-017-18339-1 · 2017 · External reference
Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study
10.1177/17562864251343583 · 2025 · External reference
Current and experimental treatments of Parkinson disease: a guide for neuroscientists
10.1111/jnc.13750 · 2016 · External reference
Different catechol-O-methyl transferase inhibitors in Parkinson's disease: a Bayesian network meta-analysis
10.3389/fneur.2021.707723 · 2021 · External reference
Dopamine agonists in Parkinson's disease: impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
2023 · External reference
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
10.1212/wnl.0b013e31821ccce4 · 2011 · External reference
Efficacy of istradefylline, an adenosine A2a receptor antagonist, as adjunctive therapy to levodopa in Parkinson's disease: a pooled analysis of 8 phase 2b/3 trials
10.3233/jpd-212672 · 2021 · External reference
Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan
10.1080/14656566.2018.1518433 · 2018 · External reference
Efficacy and safety of istradefylline for Parkinson's disease: a systematic review and meta-analysis
10.1016/j.neulet.2022.136515 · 2022 · External reference
Clinical efficacy of istradefylline versus rTMS on Parkinson's disease in a randomized clinical trial
10.1185/03007995.2015.1086994 · 2015 · External reference
